Drug Trial Radar · NCT06690177
Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Jan 10, 2027
Primary completion
Nov 4, 2028
Study completion Jan 16, 2029
Sponsor
- Lead sponsor
- MediWound LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are: * To evaluate the safety of EscharEx and its placebo Gel Vehicle compared to non-surgical standard of care (NSSOC) * To assess the efficacy of EscharEx (EX-03 5% formulation) compared to placebo control and compared to NSSOC.
Conditions
- Venus Leg Ulcers
Interventions
EscharEx (EX-03)Drug
a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
Placebo (Gel vehicle)Drug
A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
Non-surgical standard of care (NSSOC)Other
Various dressings and Collagenase
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence (number of patients) of systemic and local adverse events (AEs) throughout the trialTime frame: Throughout the study (week 2- week 17)
- Number of patients with Clinically significant changes in vital signs during the Daily Visits Period,Time frame: Weeks 2-3 (14 days)
- Number of patients with Clinically significant changes in clinical laboratory parametersTime frame: Weeks 2-3 (14 days)
- Time to complete wound closureTime frame: Weeks 2-17
- Incidence of complete wound closureTime frame: 2-17 weeks
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Nova Medical Research
Maimi, Florida
Wojskowy Instytut Medyczny
Warsaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.